Linker-Israeli M, Billing R J, Foon K A, Terasaki P I
J Immunol. 1981 Dec;127(6):2473-7.
Two cytotoxic monoclonal antibodies (D5D6 and C10H5) were raised to acute myelogenous leukemia (AML) cells. One of them, D5D6, reacted with 100% of the cells from 44/50 AML patients. The second, C10H5, reacted with 100% of the cells from 13/39 AML patients. D5D6 and C10H5 were cytotoxic to 100% of the monocytes from all healthy donors tested. Apart from monocytes, these antibodies did not react with any other peripheral blood cells from normal donors or with cancerous cells either from cell culture lines or from patients with chronic myelogenous leukemia (CML), lymphoid leukemias, or solid tumors. These antibodies inhibited the growth of the myeloid-monocytic stem cell, the CFU-C, and reacted with a minor population of normal bone marrow cells by immunofluorescence. Both D5D6 and CH5 have potential utility for the differential diagnosis of acute leukemia, for the detection of early leukemic relapse, and for enrichment of human stem cells.
制备了两种针对急性髓性白血病(AML)细胞的细胞毒性单克隆抗体(D5D6和C10H5)。其中一种,D5D6,与50例AML患者中44例患者的100%细胞发生反应。另一种,C10H5,与39例AML患者中13例患者的100%细胞发生反应。D5D6和C10H5对所有检测的健康供体的单核细胞均具有100%的细胞毒性。除单核细胞外,这些抗体不与正常供体的任何其他外周血细胞反应,也不与细胞系或慢性髓性白血病(CML)、淋巴白血病或实体瘤患者的癌细胞反应。这些抗体抑制髓单核干细胞(CFU-C)的生长,并通过免疫荧光与少数正常骨髓细胞发生反应。D5D6和C10H5在急性白血病的鉴别诊断、早期白血病复发检测以及人类干细胞富集方面均具有潜在应用价值。